Rapid conjugation of antibodies to toxins to select candidates for the development of anticancer Antibody-Drug Conjugates (ADCs)

Antibody-Drug Conjugates (ADCs) developed as a targeted treatment approach to deliver toxins directly to cancer cells are one of the fastest growing classes of oncology therapeutics, with eight ADCs and two immunotoxins approved for clinical use. However, selection of an optimum target and payload c...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:Sci Rep
Autori principali: Hoffmann, Ricarda M., Mele, Silvia, Cheung, Anthony, Larcombe-Young, Daniel, Bucaite, Gintare, Sachouli, Eirini, Zlatareva, Iva, Morad, Hassan O. J., Marlow, Rebecca, McDonnell, James M., Figini, Mariangela, Lacy, Katie E., Tutt, Andrew J. N., Spicer, James F., Thurston, David E., Karagiannis, Sophia N., Crescioli, Silvia
Natura: Artigo
Lingua:Inglês
Pubblicazione: Nature Publishing Group UK 2020
Soggetti:
Article
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC7264231/
https://ncbi.nlm.nih.gov/pubmed/32483228
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/s41598-020-65860-x
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi